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Abstract
Histatins are a group of antimicrobial peptides, found in the saliva of man and some higher primates,
which possess antifungal properties. Histatins bind to a receptor on the fungal cell membrane and
enter the cytoplasm where they target the mitochondrion. They induce the non-lytic loss of ATP
from actively respiring cells, which can induce cell death. In addition, they have been shown to
disrupt the cell cycle and lead to the generation of reactive oxygen species. Their mode of action is
distinct from those exhibited by the conventional azole and polyene drugs, hence histatins may have
applications in controlling drug-resistant fungal infections. The possibility of utilising histatins for
the control of fungal infections of the oral cavity is being actively pursued with the antifungal
properties of topical histatin preparations and histatin-impregnated denture acrylic being evalu-
ated. Initial clinical studies are encouraging, having demonstrated the safety and efficacy of histatin
preparations in blocking the adherence of the yeast Candida albicans to denture acrylic, retarding
plaque formation and reducing the severity of gingivitis. Histatins may represent a new generation
of antimicrobial compounds for the treatment of oral fungal infections and have the advantage,
compared with conventional antifungal agents, of being a normal component of human saliva with
no apparent adverse effects on host tissues and having a mode of action distinct to azole and
polyene antifungals.
Histatins — salivary antimicrobial peptides
Histatins are small histidine-rich cationic peptides ranging in size from 7 to 38 amino-acid
residues in length. They are secreted by the parotid and sub-mandibular salivary glands
in man and some higher primates and are present in saliva at concentrations in the range
50–425 (Helmerhorst et al 1997). Histatins manifest an in vivo IC50 (the concentra-
tion which inhibits growth by 50%) value of approximately 1.4M (Helmerhorst et al
1997). Histatins 1, 3 and 5 contain 38, 32 and 24 amino-acid residues, respectively, and
the sequence of the first 22 amino acids of each histatin is identical. Histatins 1 and 3 are
products of different genes while histatin 5 is a proteolytic cleavage product of histatin 3
(Oppenheim et al 1988).
Histatins represent a group of antimicrobial peptides with some antibacterial prop-
erties and significant antifungal properties (Oppenheim et al 1988). The oral cavity is
susceptible to a range of bacterial and fungal infections and histatins may have evolved
to control infection in this region. Higher levels of histatins are present in the saliva of
patients with recurrent oral candidosis than in un-infected controls, indicating their
potential role in curtailing disease in cases of persistent infection (Bercier et al 1999).
The elevated levels present in cases of recurrent infections may assist in curtailing more
serious infection or the dissemination of the infection to other parts of the body. In
contrast, however, the production of histatins decreases with age, as the incidence of
oral fungal infection rises (Johnson et al 2000).
Histatins are active against a range of pathogenic yeast and filamentous fungi
resistant to conventional azole and polyene antifungal drugs (Helmerhorst et al 1999a).
Histatin 5 is the most active histatin against the pathogenic yeast Candida albicans,
which is a normal component of the body flora but is capable of causing lesions in the
mouths of immuno-compromised patients. Histatin 5 retards the transition of C. albi-
cans from the blastospore to the hyphal stage of growth — a process that may assist in
arresting tissue penetration by the fungus (Helmerhorst et al 1997). Histatins are also
capable of killing the yeast Cryptococcus neoformans (Tsai
1998) and Candida dubliniensis (a close relative of C. albi-
cans) is susceptible to the effects of histatin 3 (Fitzgerald
et al 2003). Although not normally associated with disease
of the oral cavity, conidia of the pulmonary pathogen
Aspergillus fumigatus demonstrate greater susceptibility to
histatin 5 than amphotericin B (Helmerhorst et al 1999a).
The efficacy of histatins in controlling fungal infection may
be seen in patients who experience xerostomia (dry mouth),
where there is an increased incidence of oral fungal infec-
tions in the absence of saliva containing these antimicrobial
peptides. Their presence in saliva in normal patients helps
to curtail (rather than eliminate entirely) the numbers of
C. albicans in the oral cavity and thus prevent disease.
Structure of histatin 5
Histatin 5 may be distinguished from the other histatins
by the ability to form -helices in aqueous trifluoroetha-
nol. This ability was initially thought to be important for
the mode of action of histatin 5 but Situ et al (2000)
demonstrated that a histatin variant (called 3P), with
reduced ability to form a helix, that was formed by repla-
cing three residues with proline, had an antifungal ability
comparable with that of histatin 5.
The fungicidal activity of histatin 5 resides in a region of
11–24 residues at the C terminal referred to as the functional
domain (Driscoll et al 1995) or dh-5 (Helmerhorst et al
1997). Mutations in histatin 5 were created by replacing
single residues and producing the altered protein in the
bacterium Escherichia coli. Variant M21 was created by
replacing Lys-13 with Thr, while M71 had Lys-13 replaced
by Glu. Both variants demonstrated reduced fungicidal
activity, indicating that the Lys-13 region was required for
antifungal activity (Tsai et al 1996). A similar strategy was
adopted in generating variants with multi-site substitutions
in the dh-5 region. Two of the synthetic peptides (dhvar1
and dhvar 2) demonstrated enhanced anti-Candida proper-
ties having an IC50 (the concentration which inhibited
growth by 50%) values of 0.6 and 0.8, respectively,
compared with an IC50 value of 1.4 for histatin 5 (Table
1). Peptides hvar1 and dhvar 2 demonstrated the ability to
inhibit the growth ofC. albicans in an agar assay, in contrast
to histatin 5, and manifested antibacterial activity against
Prevotela intermedia, Streptococcus mutans and methicillin-
resistant Staphylococcus aureus (Helmerhorst et al 1997).
The potential therapeutic application of dhvar 1 and dhvar 2
was abandoned when it was discovered that both displayed
haemolytic activity in-vivo (Helmerhorst et al 1997).
Mode of action of histatins
Histatins demonstrate significant antifungal activity and
represent an important element of the local immune
response in the oral cavity. Understanding their mode of
action may allow an enhancement (or fine-tuning) of their
activity and open the possibility of employing them as
antifungals, either as free agents or incorporated into
materials that would normally be located in the oral cavity
(e.g. denture acrylic, prosthetic implants). While histatins
can manifest significant anti-Candida properties, their
mode of action remains to be fully characterised.
Histatin 5 was demonstrated to be capable of killing
C. albicans pre-loaded with calcein without inducing signifi-
cant release of the fluorescent dye, indicating that lysis of
the cell membrane was not a significant effect of the peptide
(Baev et al 2002). Histatins are also capable of killing spher-
oplasts (osmotically fragile cells retaining fragments of cell
wall) of C. albicans, demonstrating that the fungal cell wall
was not a target for their action (Driscoll et al 1996).
Histatins appear to target a specific binding site in the
fungal cell. Using cells fractionated with glass beads and
separated by SDS-PAGE it was possible to demonstrate
binding of 125I-histatin 5 to a protein of approximately 67
kDa, which may reside in the plasma membrane of the
intact cell (Edgerton et al 1998). Recent work has demon-
strated that histatin 5 binds heat shock protein 70 (Ssa1/2)
— a protein located in the fungal cell envelope. Fungal
mutants deleted in the genes for Ssa1/2 synthesis show a
low level of susceptibility to histatin 5 compared with the
unaltered parental isolate (Li et al 2003). It is unclear how
histatin gains access to this binding site but it may cross the
cell wall of C. albicans using an existing transporter and
then target the binding site in the plasma membrane.
One of the first indications that histatin 5 targets the
mitochondrion came from the observation that non-
respiring cells were resistant to its activity (Helmerhorst
et al 1999b). Fungal cells incapable of respiration (respira-
tory-deficient or petite mutants) are resistant to the action
of histatins and C. albicans cells treated with the respira-
tion inhibitor sodium azide are resistant to histatin 5
(Gyurko et al 2000). FITC-labelled histatin 5 accumulated
in respiring C. albicans cells but not in those cells treated
with azide, indicating the requirement for mitochondrial
Table 1 Amino-acid sequences of histatin 5 and derivatives.
Peptide Sequence IC50 Antifungal on agar
Histatin 5 DSHAKRHHGYKRKFHEKHHSHRGY 1.4M No
Dhvar 1 KRLFKELKFSLRKY 0.6M Yes
Dhvar 2 KRLFKELLFSLRKY 0.8M Yes
Adapted from Helmerhorst et al (1997).
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function for histatin activity. The histatin 5 appeared to
accumulate in discrete regions of the cell, which were later
identified as mitochondria using a specific mitochondrial
stain (mitotracker orange).
Histatin 5 shares a number of structural similarities
with mitochondrial pre-sequences, which are basic peptides
that target the mitochondrion. Consequently, once histatin
5 crosses the plasma membrane, it may be attracted to
the mitochondrion in a similar manner as mitochondrial
pre-sequences (Helmerhorst et al 1999b). It has been postu-
lated that cardiolipin (diphosphatidylglycerol), a negatively
charged phospholipid in themitochondrialmembrane, which
attracts mitochondrial pre-sequences, may serve to attract
histatin 5 towards the mitochondrion (Helmerhorst et al
1999b). Once histatin binds the mitochondrion, it appears
to induce the release of ATP into the cytoplasm. C. albicans
exposed to histatin 5 demonstrate a reduction in intracellular
ATP levels and there is a corresponding elevation in extra-
cellular ATP. Cells treated with the respiration uncouplers
CCCP, azide or cyanide and subsequently exposed to histatin
5 show unchanged ATP levels, indicating that respiration is
essential for histatin activity to occur (Helmerhorst et al
1999b; Koshlukova et al 1999). These finding suggest the
existence of a relationship between ATP efflux and cell
death. ATP may exit C. albicans cells via ATP-binding
cassette (ABC) proteins. One suggestion for the fungicidal
activity of histatin 5 is that, following non-lytic release of
ATP from the cell, extracellular ATP activates a purigenic-
like receptor that triggers cell death (Koshlukova et al 1999).
The loss of ATP in itself could also contribute to
the demise of the cell. In addition to their effect on ATP
levels within fungal cells, recent work has indicated that the
fungicidal activity of histatin 5 may be mediated through the
generation of reactive oxygen species (ROS) (Helmerhorst
et al 2001). Treatment of C. albicans with histatin-5 induced
the formation of ROS as measured using an oxygen radical
sensitive probe (dihydroethidium). ROS could disrupt the
cell organelle structure or function, or induce lethal DNA
damage. Histatin 5 has also been shown to disrupt the cell
cycle in C. albicans, halting cells in the G1 phase with a
concomitant effect on the regulation of cell volume homo-
eostasis, which is correlated with ATP loss (Baev et al 2002).
The current state of knowledge regarding the mode of
action of histatins can be summarised as follows (Figure 1):
histatins bind a specific receptor in C. albicans , cross the
plasma membrane and are released into the cytoplasm (A
in Figure 1); they specifically target the mitochondrion (B)
and induce the non-lytic release of ATP, perhaps through
activation of ABC proteins (C); the released ATP activates
purigenic receptors (D) or the energy loss (E) inactivates
the cell’s ability to respire; histatins cause G1 arrest (F); the
generation of ROS may damage membranes, DNA or
organelles (G) and represents the final insult leading to
the demise of the fungal cell (Helmerhorst et al 2001).
Therapeutic potential of histatins
Histatin 5 possesses potent antifungal properties and has
the advantage over conventional synthetic azole or poly-
ene antifungals of being a naturally occurring compound
in man, with no known cross-reactivity with human cells
or tissues. These qualities make it an ideal compound for
development as an antifungal agent in the treatment of
fungal infections of the oral cavity. In addition, the dis-
tinct mode of action displayed by histatin 5, compared
with that of azoles or polyenes (Tsai & Bobek 1997), may
facilitate its use in situations where resistance to conven-
tional antifungals has emerged (White et al 1998). It has
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Figure 1 The effect of histatin 5 on C. albicans. Histatin 5 targets the mitochondrion (B), induces the release of ATP (C) and affects the
ability of the cell to respire (E). ATP loss may activate a cell death pathway (D). Histatins also cause the generation of reactive oxygen species
(G) and induce G1 phase arrest of the nucleus (F).
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been suggested that the antifungal potential of histatins
could be exploited by inclusion in topical gels or denture
acrylic, or as a component in the formulation of artificial
saliva to combat xerostomia (Tsai & Bobek 1998).
Topical histatin gels have been tested for their efficacy
in controlling gingivitis in man (Paquette et al 2002).
Histatin concentrations of 0.0625, 0.125 and 0.375%
were self-applied by patients twice daily for the treatment
of gingivitis and plaque development. Administration of
gels improved the condition but, more importantly, this
work demonstrated the safety and tolerance of using
repeated doses of histatin gels in controlling oral disease.
The ability to localise histatins in dentures, or other
synthetic oral implants, would be beneficial in that the
antifungal properties of the histatin would prevent coloni-
sation of the material itself and leaching from the structure
might also contribute to the control of yeast in the oral
cavity at sites distant from the structure. Surface-modified
denture resin manufactured from poly(methyl metha-
crylate) allowed enhanced adsorption and desorption of
histatin 5 (Edgerton et al 1995). The modified material
demonstrated anti-Candida activity and inhibited the
adherence of the yeast, thus preventing the development
of a biofilm on the surface. The adherence of C. albicans to
oral tissues and dental appliances is critical to its success in
colonising the oral cavity (Cotter & Kavanagh 2000) and
the ability of histatin 5 to inhibit this phenomenon may
retard fungal colonisation and dissemination.
A number of histatin variants have been assessed for
their antifungal activity. Variant M21 (described earlier)
was found to be less potent than histatin-5 (Tsai et al
1996). Dhvar1 and dhvar 2 (multi-site substitutions in
the dh-5 region) displayed lower antifungal activity than
histatin 5 (Helmerhorst et al 1997). The variants displayed
activity against a number of bacteria but their haemolytic
activity rendered them unsuitable for future development.
The efficacy of dhvar 1 and histatin 5 was assessed using
xanthan as a delivery vehicle (Ruissen et al 1999). The
results demonstrated an increase in cidal activity of the
peptides in the presence of xanthan and indicated that this
medium would be suitable for use in situations where
retention of the peptide was critical. The nature of the
matrix can influence the activity and retention of histatins
to a significant degree. In a study of three polymeric
materials, it was established that optimum activity was
achieved in uncharged hydroxyethylcellulose rather than
xanthan or negatively charged carboymethylcellulose but
that in saliva substitutes xanthan is more suitable because
of its rheological properties (Ruissen et al 2002). It was
suggested that xanthan should be further evaluated as a
vehicle for delivering histatins but that the reductive effect
of this polymer should be counteracted by increasing the
dose of histatin present in the medium.
Conclusion
Histatins are a group of antimicrobial peptides that show
pronounced antifungal activity and are particularly active
against the yeast C. albicans. They target the mitochon-
drion and have a mode of action distinct from those of the
conventional azole and polyene antifungals. Histatins may
have applications in situations where conventional drugs
are of limited use due to the appearance of drug resistance.
The fact that histatins are a normal component of human
saliva indicates that they should be well tolerated if
applied clinically. The ability to synthesise quantities of
recombinant histatins may allow their use as topical gels
or incorporation into denture acrylic for the control of a
range of acute and chronic oral fungal infections.
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